Sofosbuvir for previously untreated chronic hepatitis C infection.

By E. Lawitz, A. Mangia, D. Wyles, M. Rodríguez-Torres, T. Hassanein, S. Gordon, M. Schultz, Mitchell N. Davis, Z. Kayali, K. Reddy and 14 more. New England Journal of Medicine, 2013

1,908 citations recorded by the source corpus.

Subfields: Emergency Medicine, Hematology, Hepatology

View Paper: https://www.semanticscholar.org/paper/362fa2f1132fe501bf3f60fb159ce78ed9b5a922

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

Citations in the corpus

Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection (2019, methodology): “(286) The use of sofosbuvir plus ribavirin is further supported by clinical trial data involving adolescents(287) and adults with genotype 2 or 3 infection.(288-291) At the time of manuscript preparation, sofosbuvir (plus ribavirin) remained the only FDA-approved DAA for children 3-11 years with gen”
EASL Recommendations on Treatment of Hepatitis C 2018. (2018, methodology): “In the FISSION trial in treatment-naïve patients treated 12 weeks [18], the SVR rate was 95% (69/73).”
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. (2014, background): “In patients who completed treatment 5 (7) 5 (45) 33 (13)‡”
EASL Recommendations on Treatment of Hepatitis C 2016. (2017, methodology): “In the FISSION trial in treatment-naïve patients treated 12 weeks [18], the SVR rate was 56% (102/183).”
EASL Recommendations on Treatment of Hepatitis C 2015. (2015, methodology): “Comments: This combination has been evaluated in the NEUTRINO Phase III trial in treatment-naïve patients [25].”
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study (2015, background): “The all-oral combination of SOF plus RBV requires 24 weeks of treatment because 12- and 16-week treatment durations were associated with lower response rates (30%-61% and 62%, respectively) in genotype 3– infected patients.(7,13,14) With 24-week treatment, lower response rates were observed in genot”
Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus (2015, methodology): “Sofosbuvir plus weight-based RBV for 24 weeks is the recommended DAA-only regimen in the United States.76,79 Based on recent data from a randomized trial demonstrating higher SVR rates than those seen with sofosbuvir and RBV for 24 weeks, the combination of sofosbuvir plus PEG-IFN and RBV for 12 wee”
Global Distribution and Prevalence of Hepatitis C Virus Genotypes (2014, background): “Genotype 3, however, which accounts for 30% of global infections, is not susceptible to the first generation of DAA protease inhibitors, and also appears less susceptible than other genotypes to sofosbuvir, the most advanced second-generation DAA therapy to date.(33,34) Ultimately, should DAA therap”